Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1-4 HCV-Infected Liver Transplant Recipients

被引：0
|
作者：
Agarwal, Kosh [1 ]
Castells, Lluis [2 ]
Mullhaupt, Beat [3 ]
Rosenberg, William M. [4 ]
McNabb, Brian L. [5 ]
Arterburn, Sarah [6 ]
Camus, Gregory [7 ]
McNally, John [5 ]
Brainard, Diana M. [5 ]
Subramanian, Mani [5 ]
Gonsalkorala, Enoka [1 ]
Londono, Maria [8 ,9 ]
Dufour, Jean-Francois [10 ]
Forns, Xavier [8 ,9 ]
机构：
[1] Kings Coll Hosp NHS Trust Fdn, London, England
[2] Hosp Univ Val dHebron, Barcelona, Spain
[3] Univ Hosp Zurich, Zurich, Switzerland
[4] UCL, Inst Liver & Digest Hlth, London, England
[5] Gilead Sci Inc, Clin Res, 353 Lakeside Dr, Foster City, CA 94404 USA
[6] Gilead Sci Inc, Biostat, 353 Lakeside Dr, Foster City, CA 94404 USA
[7] Gilead Sci Inc, Virol, 353 Lakeside Dr, Foster City, CA 94404 USA
[8] Hosp Clin Barcelona, CIBEREHD, Barcelona, Spain
[9] IDIBAPS, Barcelona, Spain
[10] Univ Bern, Bern, Switzerland
来源：
HEPATOLOGY | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1069
引用
收藏
页码：571A / 571A
页数：1
相关论文
共 50 条
  • [1] Sofosbuvir/velpatasvir for 12 weeks in genotype 1-4 HCV-infected liver transplant recipients
    Agarwal, Kosh
    Castells, Lluis
    Mullhaupt, Beat
    Rosenberg, William M. C.
    McNabb, Brian
    Arterburn, Sarah
    Camus, Gregory
    McNally, John
    Stamm, Luisa M.
    Brainard, Diana M.
    Subramanian, G. Mani
    Marino, Zoe
    Dufour, Jean-Francois
    Forns, Xavier
    JOURNAL OF HEPATOLOGY, 2018, 69 (03) : 603 - 607
  • [2] SOFOSBUVIR/VELPATASVIR FOR 12 WEEKS IN GENOTYPE 1-4 HCV-INFECTED LIVER TRANSPLANT RECIPIENTS
    Agarwal, Kosh
    Castells, Luis
    Mullhaupt, Beat
    MacDonald, Douglas C.
    McNabb, Brian
    Arterburn, Sarah
    Camus, Gregory
    McNally, John
    Brainard, Diana M.
    Subramanian, G. Mani
    Yip, Christina Sze Man
    Huang, Hai Cheng
    Gonsalkorala, Enoka
    Londono, Maria
    Dufour, Jean-Francois
    Forns, Xavier
    GUT, 2018, 67 : A98 - A99
  • [3] A Randomized Phase 3 Trial of Sofosbuvir/Velpatasvir/Voxilaprevir for 8 Weeks Compared to Sofosbuvir/Velpatasvir for 12 Weeks in DAA-Naive Genotype 1-6 HCV-Infected Patients: The POLARIS-2 Study
    Jacobson, Ira M.
    Asselah, Tarik
    Nahass, Ronald
    Bhandari, Bal R.
    Tran, Albert
    Hyland, Robert H.
    Stamm, Luisa M.
    Dvory-Sobol, Hadas
    Zhu, Yanni
    Brainard, Diana M.
    Subramanian, Mani
    McHutchison, John G.
    Shafran, Stephen
    Davis, Mitchell
    Stedman, Catherine A.
    Lawitz, Eric
    Gane, Edward J.
    HEPATOLOGY, 2016, 64 (06) : 1126A - 1126A
  • [4] RESISTANCE ANALYSIS OF GENOTYPE 1 OR 3 HCV-INFECTED PATIENTS TREATED WITH SOFOSBUVIR/VELPATASVIR+GS-9857 FOR 6 OR 8 WEEKS
    Gane, E.
    Svarovskaia, E. S.
    Dvory-Sobol, H.
    Hyland, R. H.
    Stamm, L. M.
    Brainard, D. M.
    Miller, M. D.
    Mo, H.
    Schwabe, C.
    Stedman, C. A.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S401 - S402
  • [5] LEDIPASVIR/SOFOSBUVIR FOR 12 OR 24 WEEKS IS SAFE AND EFFECTIVE IN KIDNEY TRANSPLANT RECIPIENTS WITH CHRONIC GENOTYPE 1 OR 4 HCV INFECTION
    Colombo, M.
    Aghemo, A.
    Liu, L.
    Hyland, R.
    Yun, C.
    Brainard, D.
    McHutchison, J.
    Bourliere, M.
    Peck-Radosavljevic, M.
    Manns, M.
    Pol, S.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S183 - S183
  • [6] Steroid use in HCV-infected liver transplant recipients
    Bruno Roche
    Didier Samuel
    Nature Reviews Gastroenterology & Hepatology, 2009, 6 : 198 - 200
  • [7] A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
    Michael Duerr
    Eva V. Schrezenmeier
    Lukas J. Lehner
    Léon Bergfeld
    Petra Glander
    Stephan R. Marticorena Garcia
    Christian E. Althoff
    Ingolf Sack
    Susanne Brakemeier
    Kai-Uwe Eckardt
    Klemens Budde
    Fabian Halleck
    BMC Nephrology, 20
  • [8] A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients
    Duerr, Michael
    Schrezenmeier, Eva V.
    Lehner, Lukas J.
    Bergfeld, Leon
    Glander, Petra
    Garcia, Stephan R. Marticorena
    Althoff, Christian E.
    Sack, Ingolf
    Brakemeier, Susanne
    Eckardt, Kai-Uwe
    Budde, Klemens
    Halleck, Fabian
    BMC NEPHROLOGY, 2019, 20
  • [9] TRANSPLANTATION Steroid use in HCV-infected liver transplant recipients
    Roche, Bruno
    Samuel, Didier
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2009, 6 (04) : 198 - 200
  • [10] EFFICACY AND SAFETY OF SOFOSBUVIR/VELPATASVIR PLUS RIBAVIRIN FOR 12 OR 24 WEEKS IN GENOTYPE 1 OR 2 HCV-INFECTED JAPANESE PATIENTS WITH PRIOR TREATMENT FAILURE TO DAA-BASED REGIMENS
    Izumi, Namiki
    Takehara, Tetsuo
    Chayama, Kazuaki
    Yatsuhashi, Hiroshi
    Takaguchi, Koichi
    Ide, Tatsuya
    Kurosaki, Masayuki
    Ueno, Yoshiyuki
    Toyoda, Hidenori
    Kakizaki, Satoru
    Tanaka, Yasuhito
    Kawakami, Yoshiiku
    Enomoto, Hirayuki
    Ikeda, Fusao
    Huang, K. C.
    De-Oertel, Shampa
    McNabb, Brian L.
    Camus, Gregory
    McNally, John
    Brainard, Diana M.
    Yip, Christina Sze Man
    Huang, Hai Cheng
    McHutchison, John G.
    Mochida, Satoshi
    Mizokami, Masashi
    GUT, 2018, 67 : A99 - A99
12345